ReviewNew microbes and new infections2026
Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.
Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yellow fever (YF) continues to cause high lethality in Colombia; timely, standardized care is critical. This guideline consolidates current evidence and frontline experience to support hospital management of non-critically ill patients with YF. It introduces an operational five-group classification (A, B1, B2, C1, C2) to guide level of care, monitoring, and escalation, complemented by NEWS2 and West Haven scores to help judgment. Recommendations cover initial assessment; laboratory tests and imaging; restriction of fluids; bleeding risk mitigation with transfusion thresholds; avoidance of hepatotoxic and nephrotoxic medications; measures to prevent mosquito exposure; and criteria for safe discharge (after 7 days from symptom onset and >72 h of fever-free status). The protocol emphasizes differential diagnosis with other etiologies of tropical/endemic fever and defines post-discharge surveillance to detect late-onset hepatitis and persistent progressive jaundice. Developed by a multidisciplinary team and endorsed by scientific societies, this context-adapted guidance aims to significantly reduce morbidity and mortality in endemic settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.